FDA Generic Biologic Decision Could Be Prompted With Petition – Barr
Executive Summary
Generic drug manufacturers may need to push FDA to make a decision on a pathway for approving generic biologic products by submitting citizen petitions, Barr Research VP-New Drug Development Robert Bill, PhD, told a Center for Business Intelligence conference Nov. 29 in Washington, D.C
You may also be interested in...
Medicare AWP Reform Could Pay For Oral Cancer Drug Coverage
Medicare AWP payment reform could free up funds to expand coverage of oral anticancer drugs, former Health Care Financing Administration head Nancy-Ann DeParle told the JP Morgan H&Q healthcare conference Jan. 7 in San Francisco
Medicare AWP Reform Could Pay For Oral Cancer Drug Coverage
Medicare AWP payment reform could free up funds to expand coverage of oral anticancer drugs, former Health Care Financing Administration head Nancy-Ann DeParle told the JP Morgan H&Q healthcare conference Jan. 7 in San Francisco
BIO Generic Biologics Position: All Products Need "Rigorous" Clinical Trials
The Biotechnology Industry Organization position statement on generic biologics is firmly against any shortcuts to market for follow-on products.